» Articles » PMID: 20020968

Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs

Overview
Publisher Informa Healthcare
Specialty Toxicology
Date 2009 Dec 22
PMID 20020968
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

ABSTRACT This investigation was undertaken to evaluate the therapeutic efficacy and safety of glycosylated undenatured type II collagen (UC-II) alone or in combination with glucosamine HCl and chondroitin sulfate in arthritic dogs. Twenty dogs divided into four groups (n = 5) were daily treated orally for 120 days: group I, placebo; group II, 10 mg UC-II; group III, 2,000 mg glucosamine + 1,600 mg chondroitin; group IV, UC-II (10 mg) + glucosamine (2,000 mg) + chondroitin (1,600 mg), followed by a 30-day withdrawal period. On a monthly basis, dogs were examined for overall pain, pain upon limb manipulation, and exercise-associated lameness. Serum samples were analyzed for markers of liver function (ALT and bilirubin) and renal function (BUN and creatinine). Body weight was also measured at a monthly interval. Dogs in group I exhibited no change in arthritic conditions. Dogs receiving UC-II alone showed significant reductions in overall pain within 30 days (33%) and pain upon limb manipulation and exercise-associated lameness after 60 days (66% and 44%, respectively) of treatment. Maximum reductions in pain were noted after 120 days of treatment (overall pain reduction, 62%; pain reduction upon limb manipulation, 91%; and reduction in exercise-associated lameness, 78%). The overall activity of the dogs in the UC-II supplemented with glucosamine and chondroitin group (group IV) was significantly better than the glucosamine + chondroitin-supplemented group (group III). Glucosamine and chondroitin alleviated some pain, but in combination with UC-II (group IV) provided significant reductions in overall pain (57%), pain upon limb manipulation (53%), and exercise-associated lameness (53%). Following withdrawal of supplements, all dogs (groups II to IV) experienced a relapse of pain. None of the dogs in any groups showed any adverse effects or change in liver or kidney function markers or body weight. Data of this placebo-controlled study demonstrate that daily treatment of arthritic dogs with UC-II alone or in combination with glucosamine and chondroitin markedly alleviates arthritic-associated pain, and these supplements are well tolerated as no side effects were noted.

Citing Articles

Efficacy and Safety of a Diet Enriched with EPA and DHA, Turmeric Extract and Hydrolysed Collagen in Management of Naturally Occurring Osteoarthritis in Cats: A Prospective, Randomised, Blinded, Placebo- and Time-Controlled Study.

Lefort-Holguin M, Delsart A, Otis C, Moreau M, Barbeau-Gregoire M, Mellet F Animals (Basel). 2024; 14(22).

PMID: 39595350 PMC: 11591455. DOI: 10.3390/ani14223298.


Effects of a feed supplement, containing undenatured type II collagen (UC II®) and Boswellia Serrata, in the management of mild/moderate mobility disorders in dogs: A randomized, double-blind, placebo controlled, cross-over study.

Stabile M, Fracassi L, Lacitignola L, Garcia-Pedraza E, Girelli C, Calculli C PLoS One. 2024; 19(10):e0305697.

PMID: 39475935 PMC: 11524509. DOI: 10.1371/journal.pone.0305697.


Evaluation of the Effects of an Undenatured Collagen Type-2-Based Nutraceutical (ARTHROSHINE HA²) on Recovery Time after TPLO in Dogs: A Prospective, Randomized Study with Objective Gait Analysis as the Primary Outcome Measure.

Assies M, Berger B, Stegen B, Rohwedder T, Doherr M, Bottcher P Animals (Basel). 2024; 14(2).

PMID: 38254467 PMC: 10812682. DOI: 10.3390/ani14020298.


Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and .

Zapata A, Fernandez-Parra R Animals (Basel). 2023; 13(5).

PMID: 36899726 PMC: 10000124. DOI: 10.3390/ani13050870.


H-NMR metabolomic profile of healthy and osteoarthritic canine synovial fluid before and after UC-II supplementation.

Stabile M, Girelli C, Lacitignola L, Samarelli R, Crovace A, Fanizzi F Sci Rep. 2022; 12(1):19716.

PMID: 36385297 PMC: 9669020. DOI: 10.1038/s41598-022-23977-1.